Previous Close | 0.0600 |
Open | 0.0550 |
Bid | 0.0550 x 0 |
Ask | 0.0600 x 0 |
Day's Range | 0.0550 - 0.0600 |
52 Week Range | 0.0200 - 0.2100 |
Volume | 55,000 |
Avg. Volume | 654,701 |
Market Cap | 7.693M |
Beta (5Y Monthly) | -11.87 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0140 |
Earnings Date | Feb. 28, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announces financial results for Q4 2020 and year end 2020.
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") at the request of the Investment Industry Regulatory Organization of Canada ("IIROC"), wishes to confirm that it is not aware of any material, undisclosed information related to the Company that would account for the recent increase in the market price and trading volume of its common shares.
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announces cessation of patient recruitment for its Phase 1 study.